于卫卫, 王华庆, 刘贤明, 钱正子, 张会来, 邱立华, 郝希山. 原发肾脏恶性淋巴瘤7例并文献复习[J]. 中国肿瘤临床, 2011, 38(6): 332-334 . DOI: 10.3969/j.issn.1000-8179.2011.06.009
引用本文: 于卫卫, 王华庆, 刘贤明, 钱正子, 张会来, 邱立华, 郝希山. 原发肾脏恶性淋巴瘤7例并文献复习[J]. 中国肿瘤临床, 2011, 38(6): 332-334 . DOI: 10.3969/j.issn.1000-8179.2011.06.009

原发肾脏恶性淋巴瘤7例并文献复习

  • 摘要: 目的:探讨原发肾脏恶性淋巴瘤 (PRL) 的发病率、 临床特征、 转移规律、治疗方法及影响预后的因素。方法:回顾性分析2000年1月至2009年1月收治的7例PRL患者的资料, 收集性别、年龄、症状、体征、病理类型、 B超、 CT、 PET-CT检查等资料并分析不同治疗方法对生存的影响及预后相关因素。结果:2000年1月至2009年1月间天津市平均人口数中PRL的发病率为6.48/1 000万。7例PRL患者中男3例, 女4例,年龄10~72岁,中位年龄55岁。首发部位以单侧肾脏多见。4例以腰痛或血尿就诊, 2例在常规体检中发现肾脏肿物,1例以低热、盗汗就诊。4例行肾脏切除术, 3例行肾脏肿物穿刺活检。病理均为非霍奇金淋巴瘤(NHL), 其中B细胞淋巴瘤 (B-NHL) 6例, T细胞淋巴瘤 (T-NHL) 1例。均接受了CHOP或CHOP样方案化疗。男、 女性平均生存期分别为9、 19.5个月, 巨块型 (是、 否) 平均生存期分别为8、 24.3个月, 体力状态评分 (PS)(0、 1、 2分) 平均生存期分别为30.5、 10.5和7.7个月, 单纯化疗与手术联合化疗的平均生存期分别为8.7、 19.8个月。结论: PRL是罕见的结外淋巴瘤。临床和影像学表现不典型, 容易误诊为 “肾癌”, 确诊依赖于组织病理学检查。治疗方式推荐手术切除+化疗 (放疗) 为主的综合治疗。预后可能与性别、 肿瘤大小、 PS评分和治疗方式有关。

     

    Abstract: Primary Renal Lymphoma:A Report of 7 Cases and Literature ReviewWeiwei YU, HuaqingWANG, Xianming LIU, Zhengzi QIAN, Huilai ZHANG, Lihua QIU, Xishan HAOCorrespondence to: HuaqingWANG, E-mail: huaqingw@163.comDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Sino-US Center for Lymphoma and Leukemia,Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaAbstract Objective: To explore the incidence rate, clinical characteristics, metastasis, treatment and prognosis of primary renallymphoma ( PRL ). Methods: Clinical data of 7 patients with PRL treated between January 2000 and January 2009 were retrospectivelyanalyzed with complete follow-up data. The clinical data included sex, age, symptoms, signs, pathological type, renal B ultrasound, CTand PET-CT imaging. Results: The incidence rate of PRL in Tianjin city was 6.58 per 10 million between January 2000 and January2009. Of the 7 patients in this study, there were 3 males and 4 females. The age at the onset of the disease ranged from 10 to 72 years,with an average of 55.5. Patients presented with unilateral renal masses. Four patients complained of lumbodynia or hematuria; two pa-tients had incidentally detected renal masses during routine physical examinations; one patient complained of fever and night sweats.All patients underwent nephrectomy and three patients underwent renal biopsy. All cases were identified as non-Hodgkin lymphomathrough histopathological examination with 6 tumors originating from B-cells and one originating from T-cells. All patients receivedCHOP or CHOP-like chemotherapy. The mean survival time for males and females was 9 and 19.5 months, respectively; the mean sur-vival time on the International prognostic index ( IPI ) ( 0, 1, 2 ) was 30.5, 10.5 and 7.7 months, respectively; the mean survival time forchemotherapy and nephrectomy combined with chemotherapy groups was 8.7 and 19.8 months, respectively. Conclusion: PRL is a rareextranodal lymphoma. It is easily misdiagnosed due to its nonspecific clinical manifestations and imaging features. The diagnosis ofPRL is confirmed through histopathological examination. Nephrectomy combined with chemotherapy can improve the prognosis. How-ever, the prognosis is still rather poor. It is most likely associated with gender, tumor size, IPI, and mode of treatment.Keywords Primary renal lymphoma; Incidence rate; Clinical characteristics; Treatment; Prognosis

     

/

返回文章
返回